GLP-1 vs SGLT2 Inhibitors: How the Two Diabetes Classes Compare

A lot of searches for "GLP-1 inhibitors" are actually after SGLT2 inhibitors — a different drug class entirely that ends up in the same ADA treatment recommendations. Both treat type 2 diabetes, both produce some weight loss, both have cardiovascular benefit. They work in completely different ways and they're used for different patient profiles.

This is the side-by-side comparison.

The two classes, at a glance

| | GLP-1 receptor agonists | SGLT2 inhibitors | | --- | --- | --- | | What they do | Mimic the GLP-1 incretin hormone | Block glucose reabsorption in the kidney | | Effect on glucose | Reduce A1c 0.5–2.0 points | Reduce A1c 0.5–1.0 points | | Effect on weight | Significant loss (5–21%) | Modest loss (3–6 lb) | | Effect on BP | Lower BP modestly | Lower BP modestly | | FDA-approved for weight loss? | Yes (Wegovy, Zepbound, Saxenda) | No | | FDA-approved for diabetes? | Yes | Yes | | FDA-approved for heart failure? | No | Yes (several agents) | | FDA-approved for CKD? | Some (semaglutide) | Yes (several agents) | | Format | Injection (mostly); some pills | Oral pills only | | Cost | Higher | Generally lower |

How they work

GLP-1 receptor agonists

GLP-1s mimic an incretin hormone:

• Stimulate glucose-dependent insulin release from the pancreas
• Suppress glucagon (reduces liver glucose output)
• Slow gastric emptying (extends satiety)
• Reduce appetite via central nervous system effects

Net result: blood sugar comes down, appetite drops substantially, and significant weight loss follows. Strong cardiovascular benefit evidence with several agents.

SGLT2 inhibitors

SGLT2 inhibitors block the sodium-glucose co-transporter 2 in the kidney's proximal tubule:

• Glucose that would normally be reabsorbed gets excreted in the urine
• Sodium and water follow — produces a mild diuretic effect
• Total caloric loss in urine produces modest weight loss
• Reduces preload and afterload on the heart

Net result: blood sugar lowers via urinary glucose excretion. Modest weight loss. Strong heart-failure and kidney protection evidence — this is where SGLT2 inhibitors really shine.

The drugs in each class

GLP-1 receptor agonists (US-approved)

| Drug | Brand(s) | Form | | --- | --- | --- | | Semaglutide | Ozempic, Wegovy, Rybelsus, Wegovy oral | Injection / oral | | Tirzepatide* | Mounjaro, Zepbound | Weekly injection | | Liraglutide | Victoza, Saxenda | Daily injection | | Dulaglutide | Trulicity | Weekly injection | | Exenatide | Byetta, Bydureon | Twice daily / weekly inj | | Lixisenatide | Adlyxin | Daily injection | | Orforglipron | Foundayo | Daily oral |

*Tirzepatide is a dual GLP-1/GIP agonist (covered with GLP-1s for practical purposes).

See GLP-1 drugs list.

SGLT2 inhibitors (US-approved)

| Drug | Brand | Form | | --- | --- | --- | | Empagliflozin | Jardiance | Daily oral | | Dapagliflozin | Farxiga | Daily oral | | Canagliflozin | Invokana | Daily oral | | Ertugliflozin | Steglatro | Daily oral | | Bexagliflozin | Brenzavvy | Daily oral |

All are once-daily tablets. No injections.

Side effects compared

GLP-1 side effects

• GI: nausea, vomiting, diarrhea, constipation (most common)
• Decreased appetite (intended)
• Injection site reactions (for injectables)
• Rare: pancreatitis, gallbladder issues
• Boxed warning: thyroid C-cell tumors in rodent studies

See GLP-1 side effects.

SGLT2 inhibitor side effects

• Urinary tract infections (more frequent due to glucose in urine)
• Genital yeast infections (more common in women)
• Increased urination, dehydration
• Diabetic ketoacidosis (DKA) — rare but serious, can occur even at normal blood sugar ("euglycemic DKA")
• Lower-limb amputation signal historically with canagliflozin (subsequently re-evaluated; not a class effect)
• Fournier's gangrene — extremely rare but a class warning
• Bone fracture risk (canagliflozin)

The SGLT2 side-effect profile is genitourinary-dominant; GLP-1 is gastrointestinal-dominant.

Cardiovascular outcomes

This is where the comparison matters most clinically.

GLP-1 RAs cardiovascular evidence

• Semaglutide (Wegovy): SELECT trial — 20% reduction in MACE in adults with established cardiovascular disease and obesity
• Liraglutide (Victoza): LEADER trial — 13% reduction in MACE in T2D
• Dulaglutide (Trulicity): REWIND trial — 12% reduction in MACE in T2D
• Exenatide ER: EXSCEL — neutral on MACE

GLP-1s show benefit in atherosclerotic CV disease — heart attack and stroke prevention is their wheelhouse.

SGLT2 inhibitors cardiovascular evidence

• Empagliflozin (Jardiance): EMPA-REG OUTCOME — 14% reduction in MACE; major reductions in heart-failure hospitalization
• Dapagliflozin (Farxiga): DECLARE-TIMI 58 — reduced HF hospitalization; renal benefit
• Canagliflozin (Invokana): CANVAS — reduced MACE and renal outcomes

SGLT2 inhibitors show benefit in heart failure and kidney disease — that's where they really win, and they're now first-line for HF with reduced ejection fraction regardless of diabetes status.

Kidney outcomes

• GLP-1s (semaglutide specifically): FLOW trial — semaglutide reduced kidney-disease progression in T2D with CKD
• SGLT2 inhibitors: Robust kidney benefit class-wide. Slow CKD progression, reduce dialysis need, even in non-diabetic CKD (dapagliflozin DAPA-CKD).

For kidney disease, SGLT2 inhibitors are usually the stronger first choice.

When each is the right answer

GLP-1 is the right answer if:

• Significant weight loss is a primary goal
• Atherosclerotic cardiovascular disease is the dominant concern
• Patient can tolerate injections (or wants oral via Rybelsus / oral Wegovy / Foundayo)
• A1c is high and needs substantial reduction

SGLT2 is the right answer if:

• Heart failure (especially HFrEF) is present or imminent
• Chronic kidney disease is a major concern
• Patient prefers a daily pill
• Lower drug cost matters
• The patient is not a candidate for substantial weight loss

Both might be used together if:

• Multiple risk factors are present (T2D + CV disease + CKD + obesity)
• The patient has stayed on metformin and needs additional control
• Insurance covers both

ADA 2025 guidelines support combination use in high-risk patients. There's no significant drug-drug interaction between the classes.

Cost comparison

| Class | Typical monthly cost (US, cash) | | --- | --- | | GLP-1 RAs (brand-name) | $1,000–$1,400 | | GLP-1 RAs (compounded) | $199–$349 | | SGLT2 inhibitors (brand-name) | $400–$600 | | SGLT2 inhibitors (with savings card) | $10–$25 | | SGLT2 inhibitors (generic — none yet but expected) | TBD |

SGLT2 inhibitors are generally substantially cheaper. Manufacturer copay cards exist for both classes.

Weight loss comparison

| Drug | Approximate weight loss | | --- | --- | | Tirzepatide 15 mg | ~21% body weight | | Semaglutide 2.4 mg | ~15% body weight | | Liraglutide 3.0 mg | ~8% body weight | | Empagliflozin 25 mg | ~3-6 lb | | Dapagliflozin 10 mg | ~3-6 lb | | Canagliflozin 300 mg | ~5-8 lb |

GLP-1s produce clinically meaningful weight loss; SGLT2 inhibitors produce modest weight loss as a side effect.

FAQ

Are GLP-1s and SGLT2 inhibitors the same thing? No. Different mechanisms entirely. GLP-1s mimic a hormone to suppress appetite; SGLT2 inhibitors block glucose reabsorption in the kidney.

Can you take a GLP-1 and an SGLT2 inhibitor together? Yes. The combination is supported by guidelines for high-risk T2D patients.

Is metformin better than either? Metformin is usually first-line for T2D when there's no cardiovascular or kidney concern. GLP-1s and SGLT2 inhibitors are first-line when those conditions are present.

Are SGLT2 inhibitors a "GLP-1 inhibitor"? No. "GLP-1 inhibitor" isn't really a drug class — most people searching that term mean either GLP-1 receptor agonists or SGLT2 inhibitors.

Which class causes weight loss? Both can, but GLP-1s cause dramatically more weight loss. SGLT2 inhibitors lose 3-8 lb on average; GLP-1s lose 15-21% of body weight.

---

This article is for educational purposes only and is not medical advice. Treatment selection depends on individual factors; consult a qualified healthcare professional.